NCCN 2016 Congress Series™: BREAST CANCER with Updates from 2015 San Antonio Breast Cancer Symposium
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The clinical evaluation and therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. Healthcare professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions, to communicate treatment options to patients effectively in order to make shared treatment decisions, and to provide optimal care for patients with breast cancer.
As the complexity and importance of screening, testing, and individualized treatment strategies for breast cancer have increased, so has clinicians’ reliance on the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines and NCCN’s educational interventions to increase knowledge and bridge the gaps between knowledge and competence.
The NCCN 2016 Congress Series™: Breast Cancer will present a comprehensive summary of the most up-to-date research and clinical data presented at the 2015 San Antonio Breast Cancer Symposium®. According to William J. Gradishar, MD (Betsy Bramsen Professor of Breast Oncology; Professor of Medicine; Director, Maggie Daley Center for Women’s Cancer Care; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Northwestern Hospital), “Health care providers caring for patients with breast cancer are increasingly challenged by new developments in disease management. The optimal treatment of breast cancer is becoming increasingly complex requiring an understanding of the biology of the disease, which, in turn, can inform treatment recommendations both locally and systemically. The SABCS Updates will review data-driven changes to the breast cancer practice guidelines affecting decisions regarding risk reduction strategies, local therapy options including surgical management, local-regional radiation therapy recommendations, and optimal systemic therapy for early-stage breast cancer and advanced disease. Defining risk of recurrence and potential benefit from specific treatment modalities for patients with early-stage disease has been the promise of genomic profile signatures and will be considered within the context of practice guidelines. Additionally, key emerging data from SABCS will be reviewed that may influence practice in the future.”
This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care/oncology professionals who manage patients with breast cancer.
Following this activity, participants should be able to:
EARLY STAGE BREAST CANCER
Adjuvant Radiation Therapy in Early Stage Breast Cancer
• Recognize key patient and clinical factors that influence adjuvant radiation treatment selection for patients with early-stage breast cancer.
Surgical Management of the Axilla in Early Stage Breast Cancer
• Recognize key patient and clinical factors that influence surgical treatment decisions for patients with early-stage breast cancer.
Role of Multigene Assays in the Management of Early Stage Breast Cancer
• Select appropriate clinical tools to estimate risk of relapse and the benefits of adjuvant systemic therapy.
MANAGEMENT OF DUCTAL CARCINOMA IN SITU (DCIS)
DCIS: Adjuvant Radiation Therapy & New Systemic Therapy Options
• Discuss and debate the rationale for adjuvant radiation therapy to treat patients with DCIS.
• Assess the risk of recurrence and select optimal treatment strategies for patients with DCIS.
Fertility Preservation in Breast Cancer
• Discuss fertility preservation options with patients to inform treatment decision making.
Use of Bone Modifying Agents in Patients with Breast Cancer
• Counsel patients about the supportive and therapeutic role of antiresorptive agents for the management of bone health.
2015 SAN ANTONIO BREAST CANCER SYMPOSIUM UPDATES
SABCS Updates: Local, Adjuvant, and Neoadjuvant Therapies
• Discuss emerging data and recent advances in the treatment of patients with breast cancer and integrate key findings into clinical practice.
• Identify emerging agents with novel mechanisms of action and, as appropriate, incorporate these into treatment strategies to optimize patient outcomes.
ADVANCED STAGE BREAST CANCER
Late Stage Breast Cancer, Including SABCS Updates
• Analyze critical clinical considerations in choosing the most appropriate treatment regimen for a given patient with advanced breast cancer.
• Compare the risks and benefits of the newer options available for the treatment of patients with HER2-positive disease to limit toxicities and optimize outcomes.
• Assess the risks and benefits of current and emerging agents in order to appropriately integrate them into the treatment of patients who have developed resistance to endocrine therapy.
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 5.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 5.0 contact hour(s) (0.5 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-015-L01-P
- 5.00 ACPE contact hours
- 5.00 AMA PRA Category 1 Credit™
- 5.08 ANCC contact hours
- 5.00 NCRA CE hours
- 5.00 Participation